The Swiss Institute of Bioinformatics has appointed David de Graaf and Alexey Nesvizhskii to serve on its scientific advisory board.
De Graaf is CEO of Selventa. Prior to that he was vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim. He has also held positions at Pfizer, AstraZeneca, and the Whitehead Institute's Center for Genome Research.
Nesvizhskii is an assistant professor at the University of Michigan, Ann Arbor, where he specializes in quantitative proteomics, with a focus on developing computational methods for processing and extracting biological information from complex proteomic datasets. His lab develops computational tools and statistical methods for mass spectrometry-based peptide and protein identification and quantification; works on establishing guidelines and standards for proteomic data analysis and publication; and creates public databases and proteomic data repositories.